by Rod Raynovich | Mar 30, 2010 | BIOgraph
US Judge invalidates cancer gene patents Intellectual Property (IP) is the raw material for the creation of biotech companies. Without an invention covered by a robust patent portfolio, venture funding can be very difficult. Since the beginning of the “genomic...
by Rod Raynovich | Mar 15, 2010 | BIOgraph
Helicos made a timely entrance in the race for genetic analysis systems with their HeliScope “true single molecule sequencer” (tSMS), “the first DNA microscope”. The technology was positioned as an alternative to DNA amplification, requiring...
by Rod Raynovich | Feb 16, 2010 | RAG
Many of the issues coming out of the healthcare reform discussion: rising medical costs, Medicare budget, need for better clinical outcomes, push for biogenerics have caused concern among investors and limited returns in the healthcare sector. Although M&A...
